On March 3, 2021, the National Medical Products Administration (NMPA) approved the use of furmonertinibb for second-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR 20 exon T790M (T790M) resistance mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.